GEM + nab-PTX Therapy for Pancreatic Body Cancer cStage IVb for Conversion Surgery: A Case Report

A 67-year-old woman presented with a chief complaint of umbilical region mass and epigastric pain. Carbohydrate antigen 19-9 (CA19-9) level was 177.5 U/mL; computed tomography (CT) showed a hypovascular mass lesion of 20 mm × 20 mm in the pancreas, infiltration into the superior mesenteric artery and dilation of the main pancreatic duct. Peritoneal dissemination to the omentum and abdominal wall was observed. The patient was diagnosed with T4N0M1, cStage IV unresectable pancreatic body cancer and was started on GEM + nab-PTX therapy. She underwent chemotherapy for 10 months for a total of 10 cycles. The CA19-9 level returned to normal, CT showed reduction in tumor size to 11 mm × 8 mm, and peritoneal dissemination also disappeared. Disappearance of peritoneal dissemination was also observed on Positron emission tomography (PET). Laparoscopic surgery was planned, and rapid pathological examination results of ascites washing cytology and peritoneal mass were negative. Laparoscopic distal pancreatectomy was then performed, which transitioned to hand-assisted laparoscopic surgery; R0 resection was achieved. The patient underwent outpatient postoperative adjuvant chemotherapy with orally administered S-1 and has been recurrence-free for 1 year postoperatively. This case demonstrates that patients with pancreatic body cancer with distant metastasis can undergo R0 resection following GEM + nab-PTX combination therapy.